Skip to content

Analgesic effects of ketamine-midazolam and apotel-ketorolac in renal colic patients

Comparison of analgesic effects of ketamine-midazolam and apotel-ketorolac in renal colic patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200422047163N1
Enrollment
200
Registered
2020-05-01
Start date
2019-12-22
Completion date
Unknown
Last updated
2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal colic. Unspecified renal colic

Interventions

Intervention 1: Intervention group: For patients in the intervention group, 0.016 mg / kg midazolam and 0.4 mg / kg ketamine based on body weight are injected. Intervention 2: Control group: For patie

Sponsors

Sanandaj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Renal colic patients whose initial pain is greater than or equal to 8 according to the Numeric Ranking Scale system

Exclusion criteria

Exclusion criteria: Patients with schizophrenia, asthma, cardiovascular disease and hypertension Significant head trauma Pregnancy or suspected Active lung infection Hemodynamic instability Respiratory distress or active hypoxemia Sensitivity to acetaminophen Severe liver failure Active liver disease Active gastric ulcer or its history Any suspicion of active bleeding Sensitivity to NSAIDs or aspirin Patients with kidney disease Taking painkillers (NSAIDs, acetaminophen, opioids) in the last 4 hours Glaucoma The patient's refusal to continue participating in the study Normal urine analysis (UA) Inability to understand the concept of NRS system

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: One, five, ten, fifteen, thirty and forty-five minutes after drug injection. Method of measurement: It will be determined based on the Numeric Rating Scale system.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAnvar Bahrami

Sanandaj University of Medical Sciences

bahramianvar92@gmail.com+98 87 3361 1231

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026